Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 11Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Sinonasal undifferentiated carcinoma 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Leukemia, Biphenotypic, Acute 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Filgrastim 4Ifosfamide 3Carboplatin 3Peripheral Blood Stem Cell Transplantation 2Immune Checkpoint Inhibitors 2Etoposide 2spartalizumab 1regorafenib 1perifosine 1pegfilgrastim 1pazopanib 1ivosidenib 1etoposide phosphate 1enasidenib 1drozitumab 1angiotensin I (1-7) 1alanosine 1abemaciclib 1Vincristine 1Trabectedin 1Topotecan 1Thiotepa 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Pharmacogenomic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Chondrosarcoma × enasidenib × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡